Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier

Linda K. Mooberry, Maya P. Nair, Sulabha Paranjape, Walter J. McConathy, Andras G. Lacko

Research output: Contribution to journalArticleResearchpeer-review

81 Citations (Scopus)

Abstract

The purpose of these studies was to determine the mechanism(s) whereby paclitaxel (PTX), is taken up by cancer cells, once encapsulated into synthetic/reconstituted high density lipoprotein (rHDL). The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor. Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism. In the presence of a 10-fold excess of plasma HDL, PTX uptake decreased to 30% of the control. These findings suggest that the incorporation of lipophilic drugs by cancer cells from rHDL nanoparticles is facilitated by a receptor mediated (SR-B1) mechanism.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalJournal of Drug Targeting
Volume18
Issue number1
DOIs
StatePublished - 1 Jan 2010

Fingerprint

HDL Lipoproteins
Paclitaxel
Scavenger Receptors
Nanoparticles
Pharmaceutical Preparations
Neoplasms
Prostatic Neoplasms

Keywords

  • Folate receptor
  • Lipid nanoparticles
  • Lipoprotein
  • Paclitaxel
  • Receptor uptake
  • Targeted drug delivery

Cite this

Mooberry, Linda K. ; Nair, Maya P. ; Paranjape, Sulabha ; McConathy, Walter J. ; Lacko, Andras G. / Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. In: Journal of Drug Targeting. 2010 ; Vol. 18, No. 1. pp. 53-58.
@article{922c0a9723904b5788928718dc2c1a99,
title = "Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier",
abstract = "The purpose of these studies was to determine the mechanism(s) whereby paclitaxel (PTX), is taken up by cancer cells, once encapsulated into synthetic/reconstituted high density lipoprotein (rHDL). The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor. Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism. In the presence of a 10-fold excess of plasma HDL, PTX uptake decreased to 30{\%} of the control. These findings suggest that the incorporation of lipophilic drugs by cancer cells from rHDL nanoparticles is facilitated by a receptor mediated (SR-B1) mechanism.",
keywords = "Folate receptor, Lipid nanoparticles, Lipoprotein, Paclitaxel, Receptor uptake, Targeted drug delivery",
author = "Mooberry, {Linda K.} and Nair, {Maya P.} and Sulabha Paranjape and McConathy, {Walter J.} and Lacko, {Andras G.}",
year = "2010",
month = "1",
day = "1",
doi = "10.3109/10611860903156419",
language = "English",
volume = "18",
pages = "53--58",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "1",

}

Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. / Mooberry, Linda K.; Nair, Maya P.; Paranjape, Sulabha; McConathy, Walter J.; Lacko, Andras G.

In: Journal of Drug Targeting, Vol. 18, No. 1, 01.01.2010, p. 53-58.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier

AU - Mooberry, Linda K.

AU - Nair, Maya P.

AU - Paranjape, Sulabha

AU - McConathy, Walter J.

AU - Lacko, Andras G.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The purpose of these studies was to determine the mechanism(s) whereby paclitaxel (PTX), is taken up by cancer cells, once encapsulated into synthetic/reconstituted high density lipoprotein (rHDL). The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor. Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism. In the presence of a 10-fold excess of plasma HDL, PTX uptake decreased to 30% of the control. These findings suggest that the incorporation of lipophilic drugs by cancer cells from rHDL nanoparticles is facilitated by a receptor mediated (SR-B1) mechanism.

AB - The purpose of these studies was to determine the mechanism(s) whereby paclitaxel (PTX), is taken up by cancer cells, once encapsulated into synthetic/reconstituted high density lipoprotein (rHDL). The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor. Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism. In the presence of a 10-fold excess of plasma HDL, PTX uptake decreased to 30% of the control. These findings suggest that the incorporation of lipophilic drugs by cancer cells from rHDL nanoparticles is facilitated by a receptor mediated (SR-B1) mechanism.

KW - Folate receptor

KW - Lipid nanoparticles

KW - Lipoprotein

KW - Paclitaxel

KW - Receptor uptake

KW - Targeted drug delivery

UR - http://www.scopus.com/inward/record.url?scp=72749122051&partnerID=8YFLogxK

U2 - 10.3109/10611860903156419

DO - 10.3109/10611860903156419

M3 - Article

VL - 18

SP - 53

EP - 58

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 1

ER -